AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy

Recruiting in Palo Alto (17 mi)

+21 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: Chinese Academy of Sciences

Stay on your current meds

No Placebo Group

Trial Summary

What is the purpose of this trial?This study seeks to develop a deep-learning-based intelligent predictive model for the efficacy of neoadjuvant chemotherapy in gastric cancer patients. By utilizing the patients' CT imaging data, biopsy pathology images, and clinical information, the intelligent model will predict the post-neoadjuvant chemotherapy efficacy and prognosis, offering assistance in personalized treatment decisions for gastric cancer patients.

Eligibility Criteria

Inclusion Criteria

You must be at least 18 years old.

You have been pathologically diagnosed with advanced gastric cancer according to the American AJCC's TNM staging standards.

You have not had any cancer treatments, surgery for local growth or distant spread before receiving neoadjuvant chemotherapy.

+3 more

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Gastric Cancer Patients Undergoing Neoadjuvant ChemotherapyExperimental Treatment1 Intervention

This group comprises participants diagnosed with advanced gastric cancer. The participants will be treated with standard neoadjuvant chemotherapy regimens recommended by clinical guidelines. Treatment details, including the generic name of the drugs, dosage form, dosage, frequency, and duration, will be recorded according to the specific regimen.